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Novel antimalarial targets and the antimalarial
pipeline
K. Chibale
University of Cape Town, Rondebosch, Cape Town,
South Africa
Relatively speaking, antimalarial drug discovery from pheno-
typic whole cell screening has been far more successful than
target-based approaches in delivering selective antimalarial drug
candidates for a variety of reasons. It has recently been demon-
strated that chances of discovering cell permeable and active
antimalarials with potentially novel modes of action are signiﬁ-
cantly maximized through phenotypic screening. Compounds may
easily be dismissed from target-based screening approaches if the
desirable activity against the target is not achieved. The identiﬁ-
cation of novel antimalarial drug targets that may be relevant at
all stages of the malaria parasite life cycle has been challenging to
say the least. The absence of ready access to enabling technolo-
gies to allow the study of the malaria parasite life cycle stages
is in part responsible for this. Some of these technologies are
starting to emerge and are facilitating the discovery and evalua-
tion of novel drug targets. Within the context of the antimalarial
pipeline, although the currently available chemotherapeutic arma-
mentarium for malaria is severely limited, re-engagement of the
pharmaceutical industry through precompetitive research consor-
tia in which there are shared resources and costs, thus mitigating
the risks involved in drug discovery, is signiﬁcantly changing the
landscape as recently demonstrated throughpartnerships between
the pharmaceutical industry and not-for-proﬁt Product Develop-
ment Partnerships (PDPs) such as Medicines for Malaria Venture
(MMV). This lecture will address platform technologies and how
these have been utilized in the discovery of novel antimalarial
drug targets. An update on the antimalarial pipeline will also be
presented. In conclusion, new and emerging enabling technologies
have facilitated the discovery of novel antimalarial drug targets and
boosted the antimalarial pipeline.
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Insecticide resistance: will mosquitoes be our
nemesis?
M. Coetzee
University of Witswatersrand, Johannesburg, South
Africa
Malaria parasites are transmitted to humans by anopheline
mosquitoes. The parasite undergoes an obligatory sexual stage
within the mosquito midgut that takes up to 14 days to com-
plete. This presents a window of opportunity for us to control the
mosquito populations before they have sufﬁcient time to become
infective. Unfortunately, both mosquitoes and parasites have been
around a lot longer than humans and so far have managed to ﬁnd
ways of getting around all the drugs and insecticides thatwe throw
at them. In Africa today there are approximately 140 recognised
species of Anopheles mosquitoes. Only 4 of these are really good
vectors of malaria parasites and are widespread over the conti-
nent. Three of them are highly adapted to humans and human
habitations and should, therefore, be easy to control using current
technology. The fourth is more cosmopolitan and is equally happy
to feed on cattle as well as humans and rest both indoors and out-
doors, making it a much more difﬁcult vector to control. All four
species have developed high levels of resistance to the insecticides
we use for vector control and given the limited number of chemi-
cals that are approved by the World Health Organization for vector
control, there is an urgent need for new and innovative methods
for controlling malaria vector mosquitoes.
http://dx.doi.org/10.1016/j.ijid.2014.03.445
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The increase of Mycobacterium tuberculosis
drug resistance in low and middle-income
countries
W. Van Gemert
WHO, Geneva, Switzerland
Background: Drug-resistant TB, and particularly multidrug-
resistant TB (MDR-TB) that is resistant to rifampicin and isoniazid,
is a major public health problem that threatens progress made in
TB care and control worldwide. WHO estimates that there were
450,000 (range: 300,000-600,000) new cases of MDR-TB world-
wide in 2012.
Objective:Topresent aglobalupdateonanti-TBdrug-resistance
surveillance.
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Methods: We analysed data on drug resistance among new and
previously treated TB cases reported by countries to WHO up to
2012. Data are collected in surveys of a representative sample of
TB patients or from surveillance systems in which diagnostic drug
susceptibility testing is routine practice, and quality-assured by the
Supranational TB Reference Laboratory Network.
Findings: In 1994-2012, surveillance data on MDR-TB were
reported from136 countriesworldwide. Global proportions of new
and previously treated TB cases with MDR-TB were 3.6% (95% CI:
2.1-5.1) and 20.2% (95% CI: 13.3-27.2), respectively. The highest
proportions are found in countries of the former Soviet Union
(FSU), where in several countries more than 20% of new cases and
more than 50% of previously treated cases haveMDR-TB. Estimated
MDR-TB incidence rates (MDR-TB cases per 100,000 population)
are highest in FSU countries and in southern Africa. Extensively
drug-resistant TB (XDR-TB) has been reported by 92 countries.
On average, an estimated 9.6% (95% CI: 8.1%–11%) of MDR-TB
cases have XDR-TB. A signiﬁcant positive association between
HIV and MDR-TB has been shown in 12 countries. Between 1994
and 2012, data on time trends in drug resistance were available
from 88 countries and 10 territories worldwide for a total of 870
country-year data points. Rates of MDR-TB in the general popula-
tion increased in Botswana, United Kingdom, and in Oblasts of the
Russian Federation and declined in Latvia, Estonia, and the United
States of America.
Conclusion: Better data from continuous surveillance or sur-
veys are required, especially from Africa and India. Trends in
MDR-TB are still unclear in most settings. Surveys should be
repeatedmore frequently usingmolecular technologies tomonitor
the MDR-TB epidemic more effectively.
http://dx.doi.org/10.1016/j.ijid.2014.03.446
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New developments in rapid diagnostics for drug
resistant tuberculosis
M.P. Nicol
University of Cape Town, Cape Town, South Africa
There has been considerable recent advance in the develop-
ment of rapid tests for diagnosis of drug-resistant tuberculosis.
These advances are primarily due to a fundamental change from
a phenotypic to genotypic approach to testing. The two most com-
monly used genotypic tests for resistance to ﬁrst-line drugs are
line probe assays and Xpert MTB/RIF. Line probe assays detect
resistance to rifampicin and isoniazid in cultured isolates of M.
tuberculosis, as well as directly in smear-positive (and possibly
smear-negative) sputum specimens. These assays are highly sensi-
tive and speciﬁc for detection of resistance to rifampicin, but less
sensitive for detection of isoniazid resistance. Xpert MTB/RIF may
be used for immediate, direct detection of rifampicin resistant M.
tuberculosis in sputum specimens, including themajority of smear-
negative specimens. Early reports showed high sensitivity and
speciﬁcity for detection of resistance, however the predictive value
of this assay for resistance may be impaired in patients at low risk
for rifampicin-resistant tuberculosis. More recent assay versions
appear to have substantially improved speciﬁcity. After rifampicin-
resistant tuberculosis is detected by one of these initial tests, there
is a need to rapidly determine susceptibility to second-line drugs.
At present, there are no highly accurate genotypic tests for predic-
tion of resistance, and prolonged culture-based phenotypic testing
is required. A line probe assay for detection of resistance to ﬂuoro-
quinolones, injectables and ethambutol in smear-positive sputum
specimens is available; however there is geographic variation in
the distribution of different resistance mutations and lack of pre-
dictable cross-resistance to different drugs in a class. This assay
is therefore speciﬁc for detection of XDR-TB, but lacks sensitiv-
ity. New developments in the ﬁeld include highly multiplexed
real-time PCR tests for detection of resistance and the use of
whole genome sequencing for broad detection of resistance muta-
tions. The ﬁeld is, at present, limited by incomplete understanding
of genotype-phenotype relationships and by the need for robust
bioinformatics pipelines to facilitate sequence analysis and infer
resistance patterns from sequence data.
http://dx.doi.org/10.1016/j.ijid.2014.03.447
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Newer and novel insights into the pathogenesis
and treatment of drug-resistant tuberculosis
K. Dheda
University of Cape Town, Cape Town, South Africa
Drug-resistant tuberculosis (MDR and XDR-TB) is a burgeoning
global health crisis with a high mortality irrespective of HIV-
status. In South Africa, despite comprising less than 3% of the total
caseload, DR-TB consumes almost half of the total national TBman-
agement budget - this is unsustainable and threatens to destabilise
national TB programs. MDR-TB has been eclipsed by the spectre
of resistance beyond XDR-TB (totally drug-resistant TB [TDR-TB]
and XXDR-TB) i.e. resistance to all or nearly all conventionally used
ﬁrst and second line TB drugs. Given the limited availability of
new drugs in a TB endemic setting, their preferred use in newer
ﬁrst line regimens, the ﬁnite nature of the drug pipeline, and the
likely rapid evolution of drug-resistance, alternative or adjunctive
therapeutic options are urgently needed. The traditional view is
that drug-resistance arises because of non-adherence or pharma-
cokinetic mismatch resulting in killing of susceptible populations
but overgrowth of resistant ones. However, several new con-
cepts have challenged this understanding, including within person
PK variability, induction of efﬂux pumps, immunopathology-
driven intrapulmonary drug gradients, pathogen-related factors,
including compensatory mutations which impact ﬁtness cost and
physiological pathways, and recognition of “super-spreaders” that
transmit the majority of disease. Several new drugs have also
emerged for the potential treatment of drug-resistant TB. Those
already in clinical use or likely to be imminently available will be
brieﬂy discussed including bedaqualine, delamanid, and linezolid.
Finally, given the seriousmortality and limited therapeutic options
in highly resistant strains the utility of novel immunotherapeutic
approaches are brieﬂy discussed.
http://dx.doi.org/10.1016/j.ijid.2014.03.448
